Compare Schwab US Large Cap Growth ETF (SCHG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs BIO-TECHNE Corp — how do they compare? Schwab US Large Cap Growth ETF trades at $35.66, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| SCHG | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $35.83 | $72.29 |
52-Week Low | $28.10 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $35.78, up 1.02% today, with a bullish technical signal from moving averages and strong trend strength (ADX). The ETF's low 0.04% expense ratio and concentrated exposure to AI-driven tech giants like Nvidia and Microsoft support growth potential, though key valuation metrics are unavailable. Recent news highlights institutional position adjustments and AI capital expenditure tailwinds.
Outlook remains positive due to AI growth catalysts and cost efficiency, but risks include high concentration in top holdings and sensitivity to tech sector volatility. Analyst sentiment is mixed, with some citing premium valuations as a concern for near-term performance.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
